A preliminary study on reduced dose (33 or 25 μg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer

Gynecological Endocrinology

Volumn 21, Issue 4, 2005, Pages 227-231

  Ku, Seung Yup ^a   Young, Sik Choi ^a   Byung, Chul Jee ^a   Chang, Suk Suh ^a   Young, Min Choi ^a   Jung, Gu Kim ^a   Shin, Yong Moon ^a   Kim, Seok Hyun ^a  

^a Seoul National University   (South Korea)

Author keywords

Controlled ovarian hyperstimulation; Gonadotropin releasing hormone agonist; Long protocol; Reduced dose

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; PROGESTERONE; TRIPTORELIN; UROFOLLITROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; EMBRYO; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; HUMAN CELL; HYPOPHYSIS; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MALE; OOCYTE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PREGNANCY RATE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; CHORIONIC GONADOTROPIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO TRANSFER; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; INFERTILITY, FEMALE; MENOTROPINS; OVARIAN FOLLICLE; OVULATION INDUCTION; RETROSPECTIVE STUDIES; TRIPTORELIN;

EID: 28844443481     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500282125     Document Type: Article

References (22)

1. Brinsden PR. A textbook of in vitro fertilization and assisted reproduction. 2nd ed. New York: Parthenon Publishing Group Inc.; 1999. pp 83-89.
2. Fenichel P, Grimaldi M, Olivero JF. Predictive value of hormonal profiles before stimulation of IVF. Fertil Steril 1989;51:845-849.
3. Scott RT, Toner JF, Mausher SJ. FSH levels on cycle day 3 are predictive of IVF outcome. Fertil Steril 1989;51:651-654.
4. Toner JP, Philput CB, Mausher SJ. Basal FSH level is a better predictor of IVF performance than age. Fertil Steril 1991;55:784-791.
5. Karande V, Jones G, Veeck L, Muasher SJ. High-dose FSH stimulation at the onset of the menstrual cycle does not improve IVF outcome of low-responder patients. Fertil Steril 1990;53:486-490.
6. Janssens RMJ, Vermeiden JPW, Lambalk CB, Schats R, Schoemaker J. Gonadotropin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF. Hum Reprod 1998;13:2386-2391.
7. Janssens RMJ, Lambalk CB, Vermeiden JPW, Schats R, Bernards JM, Rekers-Mombarg LT, Schoemaker J. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000;15:2333-2340.
8. Sandow J, Donnez J. Clinical pharmacokinetics of LHRH analogues. In: Brosens I, Jacob HS, Runnenbaum B, editors. LHRH analogues in gynaecology. Lancashire: Parthenon Publishing; 1990. pp 17-31.
9. Takeuchi S, Minoura H, Shibahara T, Tsuiki Y, Noritaka F, Toyoda N. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2001;76:532-537.
10. Leondires MP, Escalpes M, Segars JH, Scott RT Jr, Miller BT. Microdose follicular phase gonadotropin-releasing hormone agonists(GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization. Fertil Steril 1999;72:1018-1023.
11. Kim SH, Ku SY, Jee BC, Suh CS, Moon SY, Lee JY. Clinical significance of transvaginal color Doppler ultrasonography of the ovarian artery as a predictor of ovarian response in controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer. J Assist Reprod Genet 2002;19:103-112.
12. Ku SY, Suh CS, Kim SH, Choi YM, Kim JG, Moon SY. A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction. Eur J Obstet Gynecol Reprod Biol 2003;109:55-59.
13. Monroe SE, Blumenfeld Z, Andreyko JL, Schriock E, Henzl MR, Jaffe RB. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin). J Clin Endocrinol Metab 1986;63:1334-1341.
14. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, Comaru-Schally AM, Schally AV. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 1982;79:1658-1662.
15. Ben-Rafael Z, Lipitz S, Bider D, Mashiach S. Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone-agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril 1991;55:272-275.
16. Broekmans FJ, Hompes PGA, Lambalk CB, Schoute E, Broeders A, Schoemaker J. Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin. Hum Reprod 1996;11:55-60.
17. Simon A, Benshushan A, Shushan A, Zajicek G, Dorembus D, Lewin A, Laufer N. A comparison between a standard and reduced dose of D-Trp-6-luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization. Hum Reprod 1994;9:1813-1817.
18. Elgendy M, Afnan M, Holder R, Lashen H, Afifi Y, Lenton W, Sharif K. Reducing the dose of gonadotrophin hormone agonist on starting ovarian stimulation: effect in ovarian response and in-vitro fertilization outcome. Hum Reprod 1998;13:2382-2385.
19. Dal Prato L, Borini A, Trevisi MR, Bonu MA, Sereni E, Flamigni C. Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study. Hum Reprod 2001;16:1409-1414.
20. Navot D, Rosenwaks Z, Anderson F, Hodgen GD. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys. Fertil Steril 1991;55:1069-1075.
21. Feldberg D, Farhi J, Ashkenazi J. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone level. Fertil Steril 1994;62:343-346.
22. Olivennes F, Righini C, Fanchin R, Torrisi C, Hazout A, Glissant M, Fernandez H, Frydman F. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle stimulating hormone concentrations on day 3. Hum Reprod 1996;11:1169-1172.